| P303 | Correlation between prior surgery and immune related gastrointestinal toxicity among women receiving olaparib and tremelimumab for the treatment of recurrent ovarian cancer | Jaryse Harris, BA; Carolyn Muller, MD; Teresa Rutledge; Olivier Rixe, MD, PhD; Aisha Sethi; Phyllis Gimotty, PhD; Katherine T. Morris, MD, FACS; Sarah F. Adams, MD; | Checkpoint blockade; Clinical trial; Immune toxicity; Surgery |
| P304 | A phase 1 study of MGD007, a humanized gpA33 x CD3 DART® protein, in combination with MGA012, an anti-PD-1 antibody, in patients with relapsed/refractory metastatic colorectal cancer | Richard Kim, MD; David P. Ryan, MD; Stacey Stein, MD; James Cleary, MD, PhD; Liqin Liu, PhD; Ralph F. Alderson, PhD; Francine Z. Chen, MD; Peter Lung, BS, HT (ASCP); Allan Reduta, BA; Syd Johnson, PhD; Jan Baughman, MPH; Ezio Bonvini; Paul Moore, PhD; Joanna Lohr, PhD; Jon M. Wigginton, MD; Jan Davidson-Moncada, MD, PhD; John D. Powderly, II, MD, CPI | Checkpoint blockade; Clinical trial; T cell; Targeted therapy |
| P305 | A phase 1, open label, dose escalation study of MGD009, a B7-H3 x CD3 DART® protein, in combination with MGA012, an anti-PD-1 antibody, in patients with relapsed or refractory B7-H3-expressing tumors | Alexander I. Spira, MD, PhD, FACP; Stacie Goldberg, MD; James Strauss, MD; Johanna Bendell, MD; Gregory Cote; E E. Rahma, MD; Marwan Fakih, MD; Ralph F. Alderson, PhD; Liqin Liu, PhD; Ross La Motte-Mohs, PhD, BS; Amy Worth; Ashley Lowe; Jan Baughman, MPH; Tony Wu, PhD; Syd Johnson, PhD; Ezio Bonvini; Paul Moore, PhD; Jon M. Wigginton, MD | Checkpoint blockade; Clinical trial; Solid tumors; T cell; Targeted therapy |
| P306 | A phase 1/2, first-in-human, dose escalation study of MGC018 (anti-B7-H3 antibody-drug conjugate) alone and in combination with MGA012 (anti-PD-1 antibody) in patients with advanced solid tumors | John D. Powderly, II, MD, CPI; Deryk Loo; Anthony Joshua, MD; Johanna Bendell, MD; Alexander I. Spira, MD, PhD, FACP; Joanna Lohr, PhD; Pepi Pencheva, MD; Jichao Sun, PhD; Jan Baughman, MPH; Ezio Bonvini; Jennifer Brown; Nehal Lakhani, MD, PhD; Jon M. Wigginton, MD | Antibody; Checkpoint blockade; Chemotherapy; Clinical trial; Solid tumors; Targeted therapy |
| P307 | An open-label, phase 1B study of NEO-PV-01 + CD40 agonist antibody (APX-005M) or Ipilimumab with Nivolumab in patients with advanced or metastatic melanoma | Omid Hamid, MD; David R. Spigel, MD; Patrick A. Ott, MD, PhD; Siwen Hu-Lieskovan, MD, PhD; Karl D. Lewis, MD; Michael S. Gordon, MD; Lisa D. Cleary; Melissa Moles; Richard B. Gaynor, MD; Matthew J. Goldstein, MD, PhD; Les H. Brail; Keith Flaherty, MD; | Checkpoint blockade; Clinical trial; Immune monitoring; Neoantigens; Vaccine |
| P308 | A Phase 1 study of MEDI5752, a bispecific antibody that preferentially targets PD-1 and CTLA-4 expressing T cells, in patients with advanced solid tumors. | Jeffery Brubaker; Ben Tran; Mark Voskoboynik; James C. Kuo; Yung-Lue Bang, MD; Hyun-Cheo Chung, MD, PhD; Myung-Ju Ahn; Sang-We Kim; Ayesh Perera; Daniel Freeman; Ikbel Achour, PhD; Raffaella Faggioni, PhD; Feng Xiao; Charles Ferte, MD, PhD; Charlotte R. Lemech, MBBS BSc(med) MD(res) | Antibody; Checkpoint blockade; Clinical study; Coinhibition; Solid tumors |
| P309 | Phase I dose-finding study of MIW815 (ADU-S100), an intratumoral STING agonist, in patients with advanced solid tumors or lymphomas | Funda Meric-Bernstam, MD; Theresa Werner; Stephen Hodi; Wells Messersmith, MD; Nancy Lewis; Craig Talluto; Mirek Dostalek; Aiyang Tao; Sarah McWhirter; Damian Trujillo; Jason J. Luke, MD, FACP | Antigen presenting cells; Clinical trial; Immune adjuvant; T cell |
| P310 | NANT Cancer Vaccine an orchestration of immunogenic cell death by overcoming immune suppression and activating NK and T cell therapy in patients with third line or greater TNBC and head & neck SCC | Mira Kistler, MD; Patrick Soon-Shiong, MD, FRCS, FACS; John Lee, MD; Chaitali Nangia, MD; Leonard Sender; Frank Jones, PhD | Adoptive immunotherapy; Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; Cytokine; NK/NK T cell; T cell; Tumor antigens; Vaccine |
| P311 | Positive identification of neoepitope specific T cell by tumor-normal DNA & RNA sequencing from breast cancer patient leading to yeast-based vaccine phase 1 trial delivering tumor specific neoepitopes | Peter A. Sieling, PhD; Steve Benz; Zach Sanborn, PhD; Kayvan Niazi; Tom King; Shahrooz Rabizadeh, PhD; Andrew Nguyen; | Clinical study; Clinical trial; Neoantigens; Proteomics; T cell; Tumor antigens; Vaccine |
| P313 | INCMGA 0012-201: A phase 2 study of INCMGA00012 in patients with metastatic Merkel cell carcinoma (mMCC) | Geoffrey T. Gibney, MD; Inderjit Mehmi, MD; Sadhna Shankar; Jeffrey Marine; Chuan Tian; Igor Puzanov, MD, MSCI, FACP | Checkpoint blockade; Clinical study; Clinical trial; Solid tumors |
| P314 | An open-label, phase 1B study of NEO-PV-01 with Pembrolizumab plus chemotherapy in patients with advanced or metastatic nonsquamous Non-small Cell Lung Cancer | Mark Awad, MD PhD; David R. Spigel, MD; Lisa D. Cleary; Melissa Moles; Richard B. Gaynor, MD; Matthew J. Goldstein, MD, PhD; Ramaswamy Govindan, MD; | Chemotherapy; Clinical study; Neoantigens; Vaccine |
| P315 | Phase I/II study of the anti–LAG-3 antibody MK-4280 in combination with pembrolizumab for the treatment of hematologic malignancies | Gareth P. Gregory; Pier L. Zinzani; John Palcza, MS; Jane Healy; Robert J. Orlowski, MD; Arun Balakumaran, PhD, MD; Philippe Armand | Checkpoint blockade; Clinical trial; Leukemia/Lymphoma; Tumor evasion |
| P316 | Phase 1b dose-escalation and dose-expansion study to evaluate safety, tolerability, pharmacokinetics, and antitumor activity of ADCT-301 (Camidanlumab Tesirine) in patients with advanced solid tumors | Rose Hales; Igor Puzanov; Shivaani Kummar, MD; Patricia LoRusso, DO; Kyri P. Papadopoulos; Francesca Zammarchi, PhD; Hans G. Cruz; Jens U. Wuerthner, MD PhD; Johanna Bendell, MD; | Antibody; Clinical study; Immune tolerance; Regulatory T cell (Treg cell); Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P318 | HITM-SURE: Phase Ib CAR-T hepatic artery infusion trial for stage IV adenocarcinoma using Pressure-Enabled Drug Delivery technology | Steven C. Katz, MD; Prajna Guha, PhD; John C. Hardaway, MD, PhD; Ethan Prince, MD; Ashley E. Moody, BSN, RN; Jill E. Slansky, PhD; Kimberly R. Jordan, PhD; Richard D. Schulick, MD, FACS; Robert Knight, MD; Jerry Zeldis, MD, PhD; Vincent A. Armenio, MD; N. Joseph Espat, MD, FACS; Richard P. Junghans, PhD, MD | CAR T cells; Clinical trial; Solid tumors; Targeted therapy; Tumor microenvironment |
| P319 | PD-1 Blockade with pembrolizumab during concurrent chemoradiation for locally advanced non-small cell lung cancer | Salma K. Jabbour, MD; Abigail Berman; Roy H. Decker, MD PhD; Andrew Zloza; Steven Feigenberg; Scott N. Gettinger, MD; Charu Aggarwal, MD MPH; Corey J. Langer, MD; Charles B. Simone, II, MD; Jeffrey Bradley; Yong Lin; Salma K. Jabbour, MD; Jyoti Malhotra, MD | Checkpoint blockade; Chemotherapy; Clinical trial; Radiotherapy; Solid tumors |
| P320 | A phase 1/1b study to evaluate the safety and tolerability of AB928, a novel dual adenosine receptor antagonist, in combination with chemotherapy in patients with breast or gynecologic malignancies | Paul de Souza, MBBS, MPH, PHD, FRACP; Chee Khoon Lee; Katrin Sjoquist; Shu Pan; Amanda Idan; Aimee K. Rieger, B.S.; Wade Berry, BA; Lixia Jin; Lisa Seitz, MSc; Devika Ashok, PhD; Matthew J. Walters, PhD; Dana Piovesan, MSc; Joanne BL. Tan, PhD; Susan J. Lee, PhD; Adam Park, BS; Daniel DiRenzo, PhD; Joyson Karakunnel, MD, MSc | Antibody; Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; Immune suppression; Solid tumors; Tumor evasion; Tumor microenvironment |
| P321 | A phase 1/1b study to evaluate the safety and tolerability of AB928, a novel dual adenosine receptor antagonist, in combination with chemotherapy in patients with gastrointestinal malignancies | Paul de Souza, MBBS, MPH, PHD, FRACP; Chee Khoon Lee; Katrin Sjoquist; Shu Pan; Amanda Idan; Aimee K. Rieger, B.S.; Wade Berry, BA; Lixia Jin; Lisa Seitz, MSc; Devika Ashok, PhD; Matthew J. Walters, PhD; Dana Piovesan, MSc; Joanne BL. Tan, PhD; Susan J. Lee, PhD; Adam Park, BS; Daniel DiRenzo, PhD; Joyson Karakunnel, MD, MSc; | Antibody; Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; Immune suppression; Solid tumors; Tumor evasion; Tumor microenvironment |
| P322 | A phase 1/1b study to evaluate the safety and tolerability of AB928, a novel dual adenosine receptor antagonist, in combination with carboplatin/pemetrexed and pembrolizumab in lung cancer patients | Paul de Souza, MBBS, MPH, PHD, FRACP; Chee Khoon Lee; Katrin Sjoquist; Shu Pan; Amanda Idan; Aimee K. Rieger, B.S.; Wade Berry, BA; Lixia Jin; Lisa Seitz, MSc; Devika Ashok, PhD; Matthew J. Walters, PhD; Dana Piovesan, MSc; Joanne BL. Tan, PhD; Susan J. Lee, PhD; Adam Park, BS; Daniel DiRenzo, PhD; Joyson Karakunnel, MD, MSc | Antibody; Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; Immune suppression; Solid tumors; Tumor evasion; Tumor microenvironment |
| P323 | A phase 1 study to evaluate the safety and tolerability of AB928, a novel dual adenosine receptor antagonist, with AB122, a programmed cell death-1 inhibitor, in patients with advanced malignancies | Lisa Seitz, MSc; Aimee K. Rieger, B.S.; Wade Berry, BA; Lixia Jin; Devika Ashok, PhD; Matthew J. Walters, PhD; Dana Piovesan, MSc; Joanne BL. Tan, PhD; Susan J. Lee, PhD; Adam Park, BS; Daniel DiRenzo, PhD; Joyson Karakunnel, MD, MSc | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Immune suppression; Solid tumors; Tumor evasion; Tumor microenvironment |
| P324 | A phase II clinical trial of Ipilimumab/Nivolumab combination immunotherapy in patients with rare upper gastrointestinal, neuroendocrine and gynaecological malignancies | Oliver Klein; Kee Damien; Ben Markman; Rachael Chang Lee, FRACP; Siddharth Menon; Jodie Palmer, BA/BSc, PhD, Grad Dip Law (IP); Andreas Behren, PhD; Jonathan S. Cebon, MD, PhD | Checkpoint blockade; Clinical trial; Immune contexture; Immune monitoring; Solid tumors |
| P325 | A phase 1 dose escalation study of TSR-033, an anti-LAG3 monoclonal antibody, in patients with advanced solid tumors | Kelly Stratton, MD; Aurélien Marabelle, MD PhD; Geoffrey Shapiro, MD, PhD; Jong Chul Park, MD; Solmaz Sahebjam, MD; Srimoyee Ghosh, PhD; Jian Chen; Taylor Eves; Ying Wang; Amita Patnaik, MD FRCP© | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Cytokine; Immune tolerance; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P326 | GARNET: Preliminary safety, efficacy, pharmacokinetic, and biomarker characterization from a phase 1 clinical trial of TSR-042 (anti-PD-1 monoclonal antibody) in patients with recurrent/advanced NSCLC | Desamparados Roda Perez, PhD, MD; Janakiraman Subramanian; Joanna Pikiel; Maria-Pilar Barretina-Ginesta; José Trigo, MD; Wei Guo; Sharon Lu; David Jenkins, PhD; Kai Yu Jen; Hadi Danaee; Steven Dunlap; Ellie Im; Victor Moreno, PhD, MD | Antibody; Biomarkers; Checkpoint blockade; Clinical trial; Solid tumors |
| P327 | Higher dose single-agent intratumoral G100 (a TLR4 agonist) results in increased biomarker activity and improved clinical outcomes in patients with follicular lymphoma | Christopher Flowers, MD, MS; Carlos Panizo; Weiyun Ai, MD, PhD; Iris Isufi, MD; Alex Herrera, MD; Nancy Bartlett, MD; Craig Okada, MD, PhD; Bela Kis, MD, PhD; Luis de la Cruz Merino Sr.; Javier Briones; Jorge Chaves, MD; Elizabeth Cull; Locke J. Bryan, MD; Roch Houot, MD, PhD; Kim Linton, PhD; Ian Chau; Gottfried von Keudell; Hailing Lu, MD, PhD; Frank Hsu, MD; Ahmad S. Halwani, MD | B cell; Biomarkers; Clinical study; Clinical trial; Gene expression; Leukemia/Lymphoma; T cell; Tumor infiltrating lymphocytes (TILs); TLR; Vaccine |
| P328 | Preoperative window of opportunity trial of nivolumab with or without tadalafil in patients with squamous cell carcinoma of the head and neck | Adam Luginbuhl, MD; Jennifer Johnson, MD; Larry Harshyne; Joseph Curry, MD; Rita Axelrod, MD; Ralph G. Zinner, MD; Benjamin Leiby, PhD; Madalina Tuluc, MD; Christopher M. Snyder; David Cognetti, MD; Ulrich Rodeck, MD PhD; Athanassios Argiris, MD PhD | Checkpoint blockade; Clinical trial; Solid tumors; Surgery; Tumor microenvironment |
| P329 | Phase 3 KEYNOTE-716 study: Adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma | Jason J. Luke, MD, FACP; Paolo A. Ascierto, MD; Matteo S. Carlino, MBBS, PhD, BMedSC, F; Alexander MM. Eggermont; Jean-Jacques Grob, MD; Axel Hauschild; John M. Kirkwood, MD; Georgina Long, MBBS, PhD, BSc, FRAC; Peter Mohr; Caroline Robert; Jeffrey E. Gershenwald, MD; Andrew Poklepovic, MD; Merrick Ross, MD; Richard A. Scolyer; James Anderson; Sama Ahsan; Nageatte Ibrahim, MD PhD; Vernon K. Sondak | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Immune adjuvant; Solid tumors |
| P330 | Harnessing the power of lymphodepletion and checkpoint blockade: A Nivolumab/Ipilimumab-primed immunotransplant for relapsed/refractory diffuse large B cell lymphoma patients | Thomas U. Marron, MD PhD; Netonia Marshall, PhD; Dana Ostrowski, BA; Amir Steinberg, MD; Linda Hammerich, PhD; Sacha Gnjatic, PhD; Nina Bhardwaj, MD, PhD; Joshua Brody, MD; | Adoptive immunotherapy; Checkpoint blockade; Clinical trial; Leukemia/Lymphoma |
| P331 | A phase 1a clinical trial of NLG802, a prodrug of indoximod with enhanced pharmacokinetic properties | Olivier Rixe, MD, PhD; Thomas George, MD; Heloisa Soares; Agnieszka Marcinowicz; Nicholas Vahanian, MD; Charles Link, Jr., MD; Edouard Dupis; Eugene P. Kennedy, MD, FACS; Mario Mautino, PhD | Clinical study; Clinical trial; Immune suppression; Solid tumors |
| P332 | CheckMate 9TM: Phase 3 study of nivolumab + cisplatin + radiotherapy in cisplatin-eligible patients with intermediate- or high-risk locally advanced squamous cell carcinoma of the head & neck | Maura L. Gillison, MD, PhD; Vincent Gregoire, MD, PhD; Makoto Tahara; Quynh Thu Le, MD; Wilfried Budach; Mark Lynch, PhD; Justin Kopit; Vijayvel Jayaprakash, MBBS, PhD; Peng Sun; Robert L. Ferris, MD, PhD | Chemotherapy; Clinical trial; Radiotherapy; Solid tumors; Targeted therapy |
| P333 | CheckMate 9TM: Phase 3 study of nivolumab + radiotherapy (RT) vs cetuximab + RT in cisplatin-ineligible patients with intermediate-/high-risk locally advanced squamous cell carcinoma of the head/neck | robert haddad, MD; Kevin Harrington, MD; Lisa Licitra, MD; Peter Brossart; Dennis Soulières; Loren K. Mell, MD; Laurence Toms; Justin Kopit; Mark Lynch, PhD; Vijayvel Jayaprakash, MBBS, PhD; Ezra Cohen, MD | Clinical trial; Radiotherapy; Solid tumors; Targeted therapy |
| P334 | AI-designed dual peptide vaccine plus novel combination adjuvant showed markedly induction of antigen-specific CTLs with disease stabilization in last line patients with GI cancers. | Masao Nakajima, MD; Shoichi Hazama; Koji Tamada, MD PhD; Keiko Udaka; Yasunari Kouki; Toshinari Uematsu; Hideki Arima; Shun Doi, PhD; Hiroto Matsui; Sinsuke Kanekiyo; Yoshitaro Shindo; Yukio Tokumitsu; Shinobu Tomochika; Shin Yoshida; Michihisa Iida; Nobuaki Suzuki; Shigeru Takeda; Shigeru Yamamoto; Shigefumi Yoshino; Tomio Ueno; Hiroaki Nagano | Clinical trial; Costimulation; Immune adjuvant; Immune suppression; Regulatory T cell (Treg cell); T cell; Vaccine |
| P335 | A phase 1 study of ALX148: CD47 blockade in combination with anticancer antibodies to bridge innate and adaptive immune responses for advanced malignancy | Nehal Lakhani, MD, PhD; Patricia LoRusso, DO; Laura Q. Chow, MD; Yung-Jue Bang, MD PhD; Philip Fanning; Yonggang Zhao, PhD, MBA; Jaume Pons; Hong Wan; Sophia S. Randolph, MD, PhD; Wells Messersmith, MD | Antigen presenting cells; Checkpoint blockade; Clinical trial; Dendritic cell; Monocyte/Macrophage; Myeloid cells; Solid tumors; Targeted therapy; Tumor evasion; Tumor microenvironment |
| P336 | An international, single-arm, phase 2 study of INCMGA00012 in patients with advanced squamous carcinoma of the anal canal (SCAC) who have progressed following platinum-based chemotherapy (NCT03597295) | Sheela Rao; May Cho; Anne Demols; Talal Kayyal; Hiral Parekh; Gerard Kennealey, MD; Chuan Tian; Melissa Catlett; Marwan Fakih, MD | Checkpoint blockade; Clinical study; Clinical trial; Solid tumors |
| P337 | Phase I dose-escalation and expansion study of intratumoral CV8102, a RNA-based TLR- and RIG-1 agonist with or without anti-PD1antibodies in patients with advanced solid tumors | Lucie Heinzerling; Juergen Krauss; Carsten Weishaupt; Patrick Terheyden; Benjamin Weide, MD; Ralf Gutzmer; Peter Mohr; Juergen C. Becker, MD, PhD; Felix Kiecker; Angelika Daehling; Fatma Doener, PhD; Regina Heidenreich; Sarah-Katharina Kays; Ute Klinkhardt, MD; Birgit Scheel; Oliver Schönborn-Kellenberger; Tobias Seibel, II; Tanja Strack; Ulrike Gnad-Vogt, MD; | Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; TLR; Tumor microenvironment |
| P338 | Phase II neoadjuvant and immunologic study using the anti B7-H3 antibody, Enoblituzumab, in patients with localized prostate cancer | Eugene Shenderov, MD, PhD; Karim Boudadi, MD; Angelo M. Demarzo, MD, PhD; Mohamad E. Allaf, MD; Onur Ertunc, MD; Igor Vidal, MD; Carolyn Chapman, AAS; Hao Wang; Jim Vasselli, MD; Jon M. Wigginton, MD; Jan Davidson-Moncada, MD, PhD; Rehab Abdallah, MB BCh; Tanya O'Neal, BS, MS; Christian Pavlovich, MD; Trinity J. Bivalacqua, MD PhD; Ashley Ross, MD; Charles G. Drake, MD, PhD; Drew M. Pardoll, MD, PhD; Emmanuel S. Antonarakis, MD; | Antibody; Checkpoint blockade; Clinical trial; Tumor microenvironment |
| P339 | HCRN GI16-288: A phase II trial of perioperative CV301 vaccination in combination with nivolumab and systemic chemotherapy for resectable hepatic-limited metastatic colorectal cancer | Kristen R. Spencer, DO, MPH; Daniella E. Portal, BS; Christopher R. Heery, MD; Lynne M. Bauman, MS; Howard Hochster, MD; Elizabeth Poplin, MD; Usha Malhotra, MD; Richard B. Alexander, MD; David A. August, MD; Timothy Kennedy, MD; Miral Grandhi, MD; Russell C. Langan, MD; Edmund C. Lattime, PhD; Dirk F. Moore, PhD; Michael P. Kane, RPh, BCOP; Liesel Dudek, RN, OCN, CCRP; Sarah Nabeel; Darren Carpizo, MD, PhD | Checkpoint blockade; Chemotherapy; Clinical trial; Immune adjuvant; Solid tumors; Surgery; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine |
| P340 | Pharmacokinetic and pharmacodynamic characterization of ALX148, a CD47 blocker, in patients with advanced malignancy and non-Hodgkin lymphoma | Feng Jin, PhD; Nehal Lakhani, MD, PhD; Patricia LoRusso, DO; Laura Q. Chow, MD; Wells Messersmith, MD; Sangetha Bollini; Laura Doyle; Steven Kauder, PhD; Philip Fanning; Jaume Pons; Sophia S. Randolph, MD, PhD; Hong Wan | Antigen presenting cells; Checkpoint blockade; Clinical trial; Monocyte/Macrophage; Myeloid cells; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P341 | Phase 1 study of CA-170, a first-in-class, orally available, small molecule immune checkpoint inhibitor (ICI) dually targeting VISTA and PD-L1, in patients with advanced solid tumors or lymphomas | Yung-Lue Bang, MD; Jeffrey A. Sosman, MD; Adil Daud, MBBS MD; Funda Meric-Bernstam, MD; Javier Garcia-Corbacho; Manish R. Patel, MD; James J. Lee, MD, PhD; Kyu-Pyo Kim; Joshua Brody, MD; Sun Young Rha; Marta Gil Martin; Santiago Ponce Aix, MD; Erika P. Hamilton, MD; Radhakrishnan Ramchandren, MD; Myung-Ju Ahn; James Spicer, MD, PhD; Simon Pacey; Gerald S. Falchook, MD; Hongwei Wang, MD, PhD; Guangxin Xu; Lisa Adams, BS; Anna W. Ma, MS; Robert Ghararvi; David Tuck; John D. Powderly, II, MD, CPI | Checkpoint blockade; Clinical study; Clinical trial |
| P342 | Nivolumab plus cisplatin/pemetrexed or cisplatin/gemcitabine as induction in resectable NSCLC | Scott Cowan, MD; Charalambos Solomides, MD; Craig D. Hooper, PhD; Larry Harshyne, PhD; Grace Lu-Yao, PhD; Hushan Yang, PhD; Linda Phan, BS; Dawn Poller, BS; Sung Whang, DNP, CRNP; Benjamin Leiby, PhD; Marie Werner-Wasik, MD; Bo Lu, MD; Jennifer Johnson, MD; Rita Axelrod, MD; Argiris Athanassios, MD PhD; Natathiel Evans, MD; Ralph G. Zinner, MD | Biomarkers; Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; Immune adjuvant; Immune monitoring; Solid tumors; Surgery; Tumor evasion; Tumor microenvironment |
| P343 | Nivolumab plus weekly carboplatin and paclitaxel as induction therapy in resectable locally advanced head and neck cancer | David Cognetti, MD; Joseph Curry, MD; Adam Luginbuhl, MD; Richard Goldman, MD; Charalambos Solomides, MD; Madalina Tuluc, MD; Stacey Mardekian, MD; Craig D. Hooper, PhD; Larry Harshyne, PhD; Grace Lu-Yao, PhD; Hushan Yang, PhD; Linda Phan, BS; Dawn Poller, BS; Benjamin Leiby, PhD; Voichita Bar-Ad, MD; Jennifer Johnson, MD; Rita Axelrod, MD; Argiris Athanassios, MD PhD; Ralph G. Zinner, MD | Biomarkers; Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; Immune adjuvant; Immune monitoring; Solid tumors; Surgery; Tumor microenvironment |
| O20 | Reprogramming suppressive myeloid cells in tumor microenvironment with pepinemab, first-in-class Semaphorin 4D Mab, enhances combination immunotherapy | Terrence L. Fisher, Jr., PhD; John E. Leonard, MD PhD; Crystal Mallow, BS; Holm Bussler, PhD; Sebold Torno, BS; Maria Scrivens; Alan Howell, MS; Leslie Balch, BS; Clint T. Allen, MD; Paul E. Clavijo, PhD; Gregory B. Lesinski, PhD, MPH; Christina Wu, MD; Brian M. Olson, PhD; Siwen Hu-Lieskovan, MD, PhD; Antoni Ribas, MD, PhD; Emily Greengard, MD; Ernest S. Smith, PhD; Maurice Zauderer, PhD; Elizabeth E. Evans, PhD; Elizabeth E. Evans, PhD; Gregory B. Lesinski, PhD, MPH; | Antibody; Antigen presenting cells; Checkpoint blockade; Immune contexture; Myeloid cells; MDSC; Pediatric tumors; Solid tumors; T cell; Tumor microenvironment |
| O21 | A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in combination with TSR-042 (anti-PD-1) in patients with colorectal cancer and post-PD-1 NSCLC and melanoma | Diwakar Davar, MD; Peter D. Boasberg, MD, FACP; Zeynep Eroglu, MD; Gerald S. Falchook, MD; Justin F. Gainor, MD; Erika P. Hamilton, MD; J. Randolph Hecht, MD; Jason J. Luke, MD, FACP; Michael Pishvaian; Antoni Ribas, MD, PhD; Judy S. Wang, MD; Kristen McEachern, PhD; Angela Waszak; Sharon Lu; Yong Li; Ying Wang; Patricia LoRusso, DO | Antibody; Checkpoint blockade; Clinical trial; Coinhibition; Solid tumors; T cell; Targeted therapy |
| O22 | Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients following progression on checkpoint inhibitors | Amod A. Sarnaik, MD; Sajeve Thomas; Diwakar Davar, MD; John M. Kirkwood, MD; Harriet Kluger, MD; Jose Lutzky, MD, FACP; Melissa Wilson; Anna C. Pavlick, MD, MBA; Brendan D. Curti, MD; Eric D. Whitman, MD, FACS; Giao Q. Phan, MD; Marc S. Ernstoff, MD; Jason Chesney, MD; Toshimi Takamura, BS; Debora Barton, MD; Sam Suzuki, MS; Lavakumar Karyampudi; Nancy L. Samberg, PhD; Maria Fardis, PhD, MBA | Adoptive immunotherapy; Clinical study; Cytokine; Immune monitoring; Immune suppression; Immune tolerance; Neoantigens; Regulatory T cell (Treg cell); Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O23 | Combination of subcutaneous selicrelumab (CD40 agonist) and vanucizumab (anti-Ang2/VEGF) in patients with solid tumors demonstrates early clinical activity and a favorable safety profile | Emiliano Calvo, MD PhD; Jan Schellens; Ignacio Matos; Elena Garralda; Morten Mau-Soerensen; Aaron Hansen; Maria Martinez-Garcia; Martijn Lolkema; Jehad Charo, PhD; Chiara Lambertini; Christoph Mancao; Katrijn Bogman; Cristiano Ferlini, MD; Martin Stern, MD; Willeke Ros, MSc; | Angiogenesis; Antibody; Antigen presenting cells; Clinical study; Clinical trial; T cell |
